Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | NADPH oxidase 1 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_127219 | All targets in OG5_127219 |
Brugia malayi | Blistered cuticle protein 3 | Get druggable targets OG5_127219 | All targets in OG5_127219 |
Loa Loa (eye worm) | blistered cuticle protein 3 | Get druggable targets OG5_127219 | All targets in OG5_127219 |
Onchocerca volvulus | Dual oxidase homolog | Get druggable targets OG5_127219 | All targets in OG5_127219 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | RNA binding protein | 0.0061 | 0.4521 | 0.4521 |
Loa Loa (eye worm) | blistered cuticle protein 3 | 0.0088 | 0.7208 | 0.7208 |
Trypanosoma cruzi | ferric reductase transmembrane protein, putative | 0.0041 | 0.2496 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.4521 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.4521 | 1 |
Leishmania major | ferric reductase, putative | 0.0041 | 0.2496 | 0.5 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0052 | 0.3611 | 0.3611 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.3611 | 0.3611 |
Brugia malayi | TAR-binding protein | 0.0061 | 0.4521 | 0.4521 |
Loa Loa (eye worm) | hypothetical protein | 0.0036 | 0.194 | 0.194 |
Trypanosoma brucei | ferric reductase transmembrane protein, putative | 0.0041 | 0.2496 | 0.5 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0061 | 0.4521 | 0.4521 |
Loa Loa (eye worm) | TAR-binding protein | 0.0061 | 0.4521 | 0.4521 |
Echinococcus multilocularis | tar DNA binding protein | 0.0061 | 0.4521 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0061 | 0.4521 | 1 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0061 | 0.4521 | 0.4521 |
Brugia malayi | RNA binding protein | 0.0061 | 0.4521 | 0.4521 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0052 | 0.3611 | 0.3611 |
Brugia malayi | Blistered cuticle protein 3 | 0.0088 | 0.7208 | 0.7208 |
Schistosoma mansoni | hypothetical protein | 0.0036 | 0.194 | 0.429 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.4521 | 1 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0115 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.4521 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 0.4521 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0052 | 0.3611 | 0.3611 |
Trypanosoma cruzi | ferric reductase transmembrane protein, putative | 0.0041 | 0.2496 | 0.5 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0036 | 0.194 | 0.194 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0115 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0047 | 0.3041 | 0.3041 |
Onchocerca volvulus | Dual oxidase homolog | 0.0088 | 0.7208 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | > 17 um | PUBCHEM_BIOASSAY: Late-stage luminescence-based cell-based dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1): Purchased analogs. (Class of assay: confirmatory) [Related pubchem assays: 2752 (Primary screen (NOX1 inhibitors, synthesized analogs set 2)), 2532 (Dose response (NOX1 inhibitors, HEK/293 cells)), 2664 (Primary screen (NOX1 inhibitors, synthesized analogs)), 1792 (Primary Screen (NOX1 inhibitors)), 2556 (Counterscreen (Xanthine oxidase inhibitors)), 2538 (Dose response screen (NOX1 inhibitors)), 1796 (Summary AID (NOX1 inhibitors)), 2773 (Primary screen (NOX1 inhibitors, synthesized analogs set 3)), 2545 (Confirmation screen (NOX1 inhibitors, HEK/293 cells)), 2539 (Counterscreen (NOX2, NOX3, NOX4 inhibitors)), 2541 (Confirmation screen (NOX1 inhibitors)), 1823 (Counterscreen (luminal))] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.